The stock of Lyell Immunopharma Inc (NASDAQ: LYEL) has decreased by -6.83 when compared to last closing price of 1.61. Despite this, the company has experienced a -7.98% fall in its stock price over the last five trading sessions. globenewswire.com reported 2024-06-26 that SOUTH SAN FRANCISCO, Calif., June 26, 2024 (GLOBE NEWSWIRE) — Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced initial clinical and translational data from its Phase 1 trial of LYL797, its first-generation reprogrammed ROR1 CAR T‑cell product candidate enhanced with proprietary anti-exhaustion technology. The initial dataset consists primarily of patients with triple-negative breast cancer (TNBC) and demonstrated dose-dependent antitumor clinical activity and the ability of LYL797 CAR T cells to proliferate, infiltrate tumors and kill cancer cells in patients with relapsed/refractory disease. Patients with TNBC treated with LYL797 had an objective response rate (ORR) of 40% and clinical benefit rate (CBR) of 60% at the 150 x 106 CAR T cell dose level, with a CBR of 38% across all dose levels evaluable to date. Common treatment-related adverse events in patients without lung metastases included Grade 1 and 2 cytokine release syndrome (CRS) and headache, and the expected cytopenia from lymphodepletion. There were no reports of immune effector cell-associated neurotoxicity syndrome (ICANS) attributed to LYL797. Pneumonitis occurred in patients with lung metastases and dose escalation is continuing separately and more gradually in those patients. No dose-limiting toxicities have been reported in patients without lung involvement. All patients are now receiving prophylactic steroids prior to LYL797 treatment.
Is It Worth Investing in Lyell Immunopharma Inc (NASDAQ: LYEL) Right Now?
The 36-month beta value for LYEL is also noteworthy at -0.53. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for LYEL is 118.69M, and at present, short sellers hold a 13.59% of that float. The average trading volume of LYEL on August 02, 2024 was 974.33K shares.
LYEL’s Market Performance
LYEL’s stock has seen a -7.98% decrease for the week, with a -0.66% drop in the past month and a -35.62% fall in the past quarter. The volatility ratio for the week is 10.23%, and the volatility levels for the past 30 days are at 9.19% for Lyell Immunopharma Inc The simple moving average for the past 20 days is -8.17% for LYEL’s stock, with a -27.97% simple moving average for the past 200 days.
Analysts’ Opinion of LYEL
Many brokerage firms have already submitted their reports for LYEL stocks, with H.C. Wainwright repeating the rating for LYEL by listing it as a “Neutral.” The predicted price for LYEL in the upcoming period, according to H.C. Wainwright is $1 based on the research report published on June 27, 2024 of the current year 2024.
JP Morgan, on the other hand, stated in their research note that they expect to see LYEL reach a price target of $5, previously predicting the price at $15. The rating they have provided for LYEL stocks is “Neutral” according to the report published on August 28th, 2023.
Morgan Stanley gave a rating of “Equal-Weight” to LYEL, setting the target price at $7 in the report published on November 14th of the previous year.
LYEL Trading at -26.34% from the 50-Day Moving Average
After a stumble in the market that brought LYEL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -53.93% of loss for the given period.
Volatility was left at 9.19%, however, over the last 30 days, the volatility rate increased by 10.23%, as shares sank -0.66% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -43.82% lower at present.
During the last 5 trading sessions, LYEL fell by -7.98%, which changed the moving average for the period of 200-days by -8.54% in comparison to the 20-day moving average, which settled at $1.6330. In addition, Lyell Immunopharma Inc saw -22.68% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LYEL starting from Klausner Richard, who sale 58,020 shares at the price of $2.28 back on Aug 15 ’23. After this action, Klausner Richard now owns 930,880 shares of Lyell Immunopharma Inc, valued at $132,286 using the latest closing price.
Stock Fundamentals for LYEL
Current profitability levels for the company are sitting at:
- -3542.85 for the present operating margin
- -289.06 for the gross margin
The net margin for Lyell Immunopharma Inc stands at -3357.94. The total capital return value is set at -0.36. Equity return is now at value -32.93, with -29.00 for asset returns.
Based on Lyell Immunopharma Inc (LYEL), the company’s capital structure generated 0.09 points at debt to capital in total, while cash flow to debt ratio is standing at -2.58.
Currently, EBITDA for the company is -213.84 million with net debt to EBITDA at 0.29. When we switch over and look at the enterprise to sales, we see a ratio of 4685.07. The liquidity ratio also appears to be rather interesting for investors as it stands at 16.51.
Conclusion
In summary, Lyell Immunopharma Inc (LYEL) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
